Skip to main content

Silexion Therapeutics Corp 8-K, filed Sep 30, 2026

Silexion Therapeutics Corp (SLXN)

8-K 2026-09-30 For: 2026-09-30
View Original
Added on September 30, 2026

About this 8-K

Silexion Therapeutics Corp filed this 8-K on September 30, 2026.

Silexion Therapeutics Corp dosed the first patient worldwide in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, beginning an approximately 18-patient safety run-in followed by an approximately 166-patient randomized expansion. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits